# SELPLG

## Overview
The SELPLG gene encodes the protein P-selectin glycoprotein ligand-1 (PSGL-1), a type I transmembrane protein that plays a pivotal role in the immune system by mediating leukocyte trafficking and adhesion. PSGL-1 is primarily expressed on the surface of leukocytes, where it facilitates the rolling and adhesion of these cells on endothelial surfaces, a critical step in the immune response to inflammation and tissue injury. The protein's interaction with selectins, such as P-selectin, is essential for leukocyte recruitment to sites of inflammation, and it also participates in intracellular signaling pathways that modulate immune cell behavior. The SELPLG gene and its encoded protein are of significant clinical interest due to their involvement in various pathological conditions, including cancer, where alterations in SELPLG expression can impact disease progression and serve as potential therapeutic targets (Wang2022SELPLG; Moore1995Pselectin; Kappelmayer2004The).

## Structure
P-selectin glycoprotein ligand-1 (PSGL-1), encoded by the SELPLG gene, is a homodimeric disulfide-linked glycoprotein. It is a type I integral membrane protein with a predicted amino acid sequence of 402 residues. The protein features a Ser/Thr/Pro-rich extracellular domain, which includes three potential sites for N-linked oligosaccharides and a cysteine residue crucial for dimerization (Moore1995Pselectin). The primary structure of PSGL-1 includes a decameric repeat region rich in serine, threonine, and proline, which is distinct from other mucin-like molecules (Furie1999The).

PSGL-1's secondary and tertiary structures are not detailed in the provided context, but its quaternary structure is characterized by its homodimeric form. The protein contains specific domains such as the lectin domain, EGF-like domain, and short consensus repeat (SCR) domains, which are common in selectin ligands (Kappelmayer2004The).

Post-translational modifications are critical for PSGL-1's function, including α1,3 fucosylation, α2,3 sialylation, and core-2 branched O-glycosylation. These modifications are essential for its binding to P-selectin, with sulfated tyrosine residues also playing a crucial role (Furie1999The). The glycan structures of PSGL-1 are mostly unfucosylated, with a minor fucosylated population (Furie1999The).

## Function
The SELPLG gene encodes P-selectin glycoprotein ligand-1 (PSGL-1), a critical protein involved in leukocyte trafficking and adhesion. PSGL-1 is primarily expressed on the microvilli of leukocytes, including neutrophils, monocytes, and lymphocytes, where it facilitates the rolling of these cells on P-selectin, a process essential for leukocyte adhesion and migration during the immune response (Moore1995Pselectin). This interaction is calcium-dependent and requires specific sialylated and fucosylated O-linked glycans on PSGL-1 for high-affinity binding to P-selectin (Moore1995Pselectin; Kappelmayer2004The).

PSGL-1's role in leukocyte rolling is crucial under both static and shear conditions, which mimic the physiological environment of blood flow. This rolling is a precursor to firm adhesion and transmigration of leukocytes into tissues, a key step in the inflammatory response (Moore1995Pselectin). The interaction between PSGL-1 and P-selectin also triggers intracellular signaling events, such as tyrosine phosphorylation, which are important for further leukocyte activation and cytokine secretion (Kappelmayer2004The). PSGL-1 is thus integral to the immune system's ability to respond to inflammation and tissue injury.

## Clinical Significance
Alterations in the expression of the SELPLG gene, also known as selectin P ligand or CD162, have been implicated in various diseases, particularly cancers. In osteosarcoma, a malignant bone tumor common in children, low SELPLG expression is associated with increased metastasis and poorer prognosis. This suggests that SELPLG could serve as a prognostic biomarker and potential therapeutic target in osteosarcoma (Wang2022SELPLG). 

In primary effusion lymphoma (PEL), SELPLG is amplified, which may contribute to the disease's pathogenesis by promoting cell migration and colonization. This amplification is part of a broader genomic imbalance observed in PEL, highlighting SELPLG's potential role in the disease's development (Luan2010Primary).

SELPLG is also highly expressed in anaplastic large T-cell lymphomas (ALCLs), where it correlates with CD30 expression and TCR signaling pathways. This expression pattern suggests that SELPLG could be a target for immunotherapy in ALCL, as it is involved in unique transcriptional networks associated with cancer-related pathways (Belmonte2021Constitutive). 

These findings underscore the clinical significance of SELPLG in various cancers, where its altered expression or amplification can influence disease progression and treatment strategies.

## Interactions
SELPLG, also known as P-selectin glycoprotein ligand-1 (PSGL-1), is involved in several critical interactions with other proteins, primarily within the immune system. It binds to selectins, including P-selectin, E-selectin, and L-selectin, facilitating leukocyte rolling and adhesion during inflammatory responses (Luan2010Primary). This interaction is crucial for leukocyte recruitment to sites of inflammation, as SELPLG acts as a ligand for these selectins, which are expressed on activated endothelial cells and platelets (Tinoco2021PSGL1).

SELPLG also functions as a signal transduction receptor, triggering intracellular signaling events upon binding to selectins (Luan2010Primary). This interaction is not only structural but also functional, as it can modulate immune cell behavior and responses. In addition to selectin binding, SELPLG can engage with other ligands independently, such as lymphoid tissue chemokines CCL19 and CCL21, and VISTA, a negative regulator of T cell responses (Tinoco2021PSGL1). These interactions highlight SELPLG's role in regulating immune responses and its potential involvement in various pathological conditions, including viral infections and cancer.


## References


[1. (Tinoco2021PSGL1) Roberto Tinoco, Emily N. Neubert, Christopher J. Stairiker, Monique L. Henriquez, and Linda M. Bradley. Psgl-1 is a t cell intrinsic inhibitor that regulates effector and memory differentiation and responses during viral infection. Frontiers in Immunology, July 2021. URL: http://dx.doi.org/10.3389/fimmu.2021.677824, doi:10.3389/fimmu.2021.677824. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2021.677824)

[2. (Moore1995Pselectin) K L Moore, K D Patel, R E Bruehl, F Li, D A Johnson, H S Lichenstein, R D Cummings, D F Bainton, and R P McEver. P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on p-selectin. The Journal of cell biology, 128(4):661–671, February 1995. URL: http://dx.doi.org/10.1083/jcb.128.4.661, doi:10.1083/jcb.128.4.661. This article has 559 citations.](https://doi.org/10.1083/jcb.128.4.661)

[3. (Wang2022SELPLG) Bingqi Wang and Yufu Sun. Selplg expression was potentially correlated with metastasis and prognosis of osteosarcoma. Pathology and Oncology Research, January 2022. URL: http://dx.doi.org/10.3389/pore.2022.1610047, doi:10.3389/pore.2022.1610047. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/pore.2022.1610047)

[4. (Furie1999The) Barbara Furie, Bruce Furie, and Jing Yang. The biology of p-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thrombosis and Haemostasis, 81(01):1–7, 1999. URL: http://dx.doi.org/10.1055/s-0037-1614407, doi:10.1055/s-0037-1614407. This article has 174 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1055/s-0037-1614407)

[5. (Luan2010Primary) Shi‐Lu Luan, Emmanuelle Boulanger, Hongtao Ye, Estelle Chanudet, Nicola Johnson, Rifat A Hamoudi, Chris M Bacon, Hongxiang Liu, Yuanxue Huang, Jonathan Said, Peiguo Chu, Christoph S Clemen, Ethel Cesarman, Amy Chadburn, Peter G Isaacson, and Ming‐Qing Du. Primary effusion lymphoma: genomic profiling revealed amplification of selplg and coro1c encoding for proteins important for cell migration. The Journal of Pathology, 222(2):166–179, September 2010. URL: http://dx.doi.org/10.1002/path.2752, doi:10.1002/path.2752. This article has 57 citations.](https://doi.org/10.1002/path.2752)

[6. (Belmonte2021Constitutive) Beatrice Belmonte, Valeria Cancila, Alessandro Gulino, Mohsen Navari, Walter Arancio, Paolo Macor, Andrea Balduit, Sara Capolla, Gaia Morello, Davide Vacca, Ines Ferrara, Giorgio Bertolazzi, Carmela Balistreri, Paolo Amico, Federica Ferrante, Antonino Maiorana, Tiziana Salviato, Pier Piccaluga, and Alessandro Mangogna. Constitutive psgl-1 correlates with cd30 and tcr pathways and represents a potential target for immunotherapy in anaplastic large t-cell lymphoma. Cancers, 13(12):2958, June 2021. URL: http://dx.doi.org/10.3390/cancers13122958, doi:10.3390/cancers13122958. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers13122958)

[7. (Kappelmayer2004The) János Kappelmayer, Béla Nagy, Kornél Miszti-Blasius, Zsuzsa Hevessy, and Hendra Setiadi. The emerging value of p-selectin as a disease marker. Clinical Chemistry and Laboratory Medicine (CCLM), January 2004. URL: http://dx.doi.org/10.1515/CCLM.2004.082, doi:10.1515/cclm.2004.082. This article has 147 citations.](https://doi.org/10.1515/CCLM.2004.082)